A detailed history of Tfb Advisors LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Tfb Advisors LLC holds 9,281 shares of GILD stock, worth $817,470. This represents 0.21% of its overall portfolio holdings.

Number of Shares
9,281
Previous 10,555 12.07%
Holding current value
$817,470
Previous $773,000 17.72%
% of portfolio
0.21%
Previous 0.27%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

SELL
$63.15 - $72.88 $80,453 - $92,849
-1,274 Reduced 12.07%
9,281 $636,000
Q1 2024

May 03, 2024

BUY
$71.58 - $87.29 $252,963 - $308,482
3,534 Added 50.33%
10,555 $773,000
Q4 2023

Jan 18, 2024

BUY
$73.27 - $83.09 $514,428 - $583,374
7,021 New
7,021 $568,000
Q2 2023

Jul 18, 2023

BUY
$76.01 - $86.7 $508,050 - $579,502
6,684 Added 138.82%
11,499 $886,000
Q1 2023

Apr 10, 2023

BUY
$77.31 - $88.08 $28,759 - $32,765
372 Added 8.37%
4,815 $399,000
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $276,887 - $397,515
4,443 New
4,443 $381,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Tfb Advisors LLC Portfolio

Follow Tfb Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tfb Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tfb Advisors LLC with notifications on news.